Chronic Idiopathic Cough Clinical Trial
Official title:
A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Idiopathic Cough.
The purpose of this study is to determine the effectiveness of XEN-D0501 over placebo in
reducing the daytime cough frequency in patients with chronic idiopathic cough.
The effectiveness of XEN-D0501 over placebo in reducing capsaicin cough responses, objective
24-hour cough frequency, hourly change in cough frequency, cough severity (via visual
analogue scale [VAS]), urge to cough (via VAS), global rating of change scale and Leicester
Cough Questionnaire (LCQ) will be evaluated.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment